| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.
|
Eur J Cancer
|
2007
|
2.36
|
|
2
|
Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry.
|
Gut
|
2005
|
2.07
|
|
3
|
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
|
Br J Cancer
|
1986
|
1.91
|
|
4
|
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.
|
Eur J Cancer
|
2003
|
1.86
|
|
5
|
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.
|
Ann Oncol
|
2009
|
1.78
|
|
6
|
Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis.
|
Br J Cancer
|
1986
|
1.45
|
|
7
|
Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
|
Br J Cancer
|
1986
|
1.44
|
|
8
|
The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.
|
Br J Cancer
|
1994
|
1.44
|
|
9
|
CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
|
Anticancer Res
|
2002
|
1.36
|
|
10
|
Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue.
|
Br J Cancer
|
2010
|
1.33
|
|
11
|
Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence.
|
Br J Cancer
|
1998
|
1.32
|
|
12
|
Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.
|
Int J Cancer
|
1987
|
1.30
|
|
13
|
Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
|
Br J Cancer
|
1991
|
1.25
|
|
14
|
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder.
|
Am J Pathol
|
2001
|
1.22
|
|
15
|
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.
|
Int J Cancer
|
2013
|
1.21
|
|
16
|
Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer.
|
Acta Oncol
|
1997
|
1.17
|
|
17
|
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.
|
J Clin Pathol
|
2006
|
1.14
|
|
18
|
Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease.
|
Cancer Res
|
1992
|
1.11
|
|
19
|
Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.
|
Br J Cancer
|
1986
|
1.06
|
|
20
|
Prognostic role of CIP2A expression in serous ovarian cancer.
|
Br J Cancer
|
2011
|
1.06
|
|
21
|
Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer.
|
Int J Cancer
|
2001
|
1.05
|
|
22
|
Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer.
|
Oncology
|
2005
|
1.03
|
|
23
|
Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer.
|
Anticancer Res
|
1996
|
1.01
|
|
24
|
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer.
|
Br J Cancer
|
2011
|
0.99
|
|
25
|
Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.
|
Br J Cancer
|
1987
|
0.98
|
|
26
|
Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.
|
Br J Cancer
|
1996
|
0.97
|
|
27
|
STn and prognosis in breast cancer.
|
Oncology
|
2001
|
0.95
|
|
28
|
Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
|
Br J Cancer
|
1987
|
0.95
|
|
29
|
Tissue expression of human chorionic gonadotropin beta predicts outcome in colorectal cancer: a comparison with serum expression.
|
Int J Cancer
|
2001
|
0.94
|
|
30
|
Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.
|
Oncology
|
2011
|
0.94
|
|
31
|
Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.
|
Anticancer Res
|
1996
|
0.94
|
|
32
|
Serum trypsinogen-2 and trypsin-2-alpha(1)-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas.
|
Int J Cancer
|
1996
|
0.93
|
|
33
|
Concentrations of human choriogonadotropin, its beta-subunit, and the core fragment of the beta-subunit in serum and urine of men and nonpregnant women.
|
Clin Chem
|
1992
|
0.93
|
|
34
|
Expression of laminin in pancreatic neoplasms and in chronic pancreatitis.
|
Am J Surg Pathol
|
1984
|
0.92
|
|
35
|
Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer.
|
Oncology
|
1996
|
0.92
|
|
36
|
Effect of intraperitoneal bupivacaine on pain after laparoscopic cholecystectomy.
|
Acta Anaesthesiol Scand
|
1995
|
0.91
|
|
37
|
Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.
|
J Clin Endocrinol Metab
|
2001
|
0.91
|
|
38
|
MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer.
|
J Clin Pathol
|
2006
|
0.90
|
|
39
|
Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer.
|
Int J Oncol
|
2006
|
0.89
|
|
40
|
Tenascin-C expression and its prognostic significance in colorectal cancer.
|
Oncology
|
2008
|
0.89
|
|
41
|
Expression of COX-2 is increased with age in papillary thyroid cancer.
|
Histopathology
|
2004
|
0.89
|
|
42
|
Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation.
|
J Clin Pathol
|
2004
|
0.89
|
|
43
|
Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus.
|
Gut
|
2003
|
0.88
|
|
44
|
A prognostic value of CA 19-9 but not of CEA in patients with gastric cancer.
|
Eur J Surg Oncol
|
1995
|
0.88
|
|
45
|
Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9.
|
Int J Cancer
|
1986
|
0.88
|
|
46
|
Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas.
|
Am J Pathol
|
2001
|
0.87
|
|
47
|
Cellular fibronectin in serum and plasma: a potential new tumour marker?
|
Br J Cancer
|
1995
|
0.87
|
|
48
|
Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis.
|
J Clin Endocrinol Metab
|
2001
|
0.86
|
|
49
|
Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer.
|
J Clin Pathol
|
2006
|
0.86
|
|
50
|
p27 expression correlates with short-term, but not with long-term prognosis in breast cancer.
|
Breast Cancer Res Treat
|
2001
|
0.84
|
|
51
|
High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer.
|
Histopathology
|
2005
|
0.84
|
|
52
|
Does Helicobacter pylori in the gastric stump increase the cancer risk after certain reconstruction types?
|
Anticancer Res
|
1998
|
0.84
|
|
53
|
Expression of p53 protein as a prognostic factor in patients with gastric cancer.
|
Eur J Cancer
|
1996
|
0.83
|
|
54
|
A prognostic value of syndecan-1 in gastric cancer.
|
Anticancer Res
|
2001
|
0.83
|
|
55
|
Increased expression of tenascin in pheochromocytomas correlates with malignancy.
|
Am J Surg Pathol
|
2001
|
0.82
|
|
56
|
Ki-67, ploidy and S-phase fraction as prognostic factors in gastric cancer.
|
Anticancer Res
|
1997
|
0.82
|
|
57
|
Sialyl Tn antigen is an independent predictor of outcome in patients with gastric cancer.
|
Int J Cancer
|
1996
|
0.81
|
|
58
|
A comparison of serum and tissue hCG beta as prognostic markers in colorectal cancer.
|
Anticancer Res
|
2001
|
0.81
|
|
59
|
Proliferative activity detected by Ki67 correlates with poor outcome in Merkel cell carcinoma.
|
Histopathology
|
2006
|
0.81
|
|
60
|
Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer.
|
Eur J Cancer
|
1996
|
0.80
|
|
61
|
Competitive enzyme immunoassay for quantification of the cellular form of fibronectin (EDAcFN) in blood samples.
|
J Immunol Methods
|
1993
|
0.80
|
|
62
|
Risk of cancer in patients with chronic pouchitis after restorative proctocolectomy for ulcerative colitis.
|
Colorectal Dis
|
2011
|
0.80
|
|
63
|
Lack of histologically suspicious features, proliferative activity, and p53 expression suggests benign diagnosis in phaeochromocytomas.
|
Histopathology
|
2003
|
0.80
|
|
64
|
Trypsinogen-1, -2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas.
|
Scand J Clin Lab Invest
|
2001
|
0.80
|
|
65
|
Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma.
|
Oncology
|
1996
|
0.80
|
|
66
|
The course of Helicobacter pylori infection after partial gastrectomy for peptic ulcer disease.
|
Hepatogastroenterology
|
1998
|
0.80
|
|
67
|
Loss of p27 expression is associated with poor prognosis in stage I-II pancreatic cancer.
|
Oncology
|
2003
|
0.80
|
|
68
|
Sialyl Tn is a frequently expressed antigen in colorectal cancer: No correlation with patient prognosis.
|
Oncology
|
1999
|
0.79
|
|
69
|
A risk score for predicting outcome in patients with gastric cancer, based on stage, sialyl-Tn immunoreactivity and ploidy--a multivariate analysis.
|
Int J Cancer
|
1996
|
0.79
|
|
70
|
Tenascin-C in primary Merkel cell carcinoma.
|
J Clin Pathol
|
2005
|
0.79
|
|
71
|
An improved method for quantification of extra domain A-containing cellular fibronectin (EDAcFN) in different body fluids.
|
Clin Chim Acta
|
1995
|
0.78
|
|
72
|
Primary lymphocytes as predictors for species differences in cytotoxic drug sensitivity.
|
Toxicol In Vitro
|
2007
|
0.78
|
|
73
|
The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.
|
Br J Cancer
|
2001
|
0.78
|
|
74
|
Laparoscopic cholecystectomy: the Finnish experience.
|
Ann Chir Gynaecol
|
1996
|
0.78
|
|
75
|
An institutional experience with 40 first lateral transperitoneal laparoscopic adrenalectomies.
|
Surg Laparosc Endosc Percutan Tech
|
2000
|
0.77
|
|
76
|
Expression of the androgen receptor and syndecan-1 in breast tissue during different hormonal treatments in cynomolgus monkeys.
|
Climacteric
|
2009
|
0.77
|
|
77
|
Genome-controlled reverse transcriptase-polymerase chain reaction for targeted gene-expression analysis.
|
Scand J Clin Lab Invest
|
2006
|
0.77
|
|
78
|
Concentration of free hCGbeta subunit in serum as a prognostic marker for squamous-cell carcinoma of the oral cavity and oropharynx.
|
Int J Cancer
|
1999
|
0.77
|
|
79
|
Preoperative serum levels of CEA and CA 242 in colorectal cancer.
|
Br J Cancer
|
1995
|
0.77
|
|
80
|
High frequency of SNAIL-expressing cells confirms and predicts metastatic potential of phaeochromocytoma.
|
Endocr Relat Cancer
|
2009
|
0.77
|
|
81
|
Time-resolved immunofluorometric assay of trypsin-1 complexed with alpha(1)-antitrypsin in serum: increased immunoreactivity in patients with biliary tract cancer.
|
Clin Chem
|
1999
|
0.76
|
|
82
|
Tumour markers and radiological examinations in the follow-up of patients with oral cancer.
|
J Craniomaxillofac Surg
|
1992
|
0.76
|
|
83
|
Short and long term outcome after laparoscopic cholecystectomy.
|
Ann Chir Gynaecol
|
1999
|
0.75
|
|
84
|
Neuropeptide S receptor 1 (NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors.
|
Virchows Arch
|
2014
|
0.75
|
|
85
|
Laparoscopic adrenalectomy for primary aldosteronism: clinical experience in 12 patients.
|
Surg Laparosc Endosc
|
1999
|
0.75
|
|
86
|
Large mesenteric mass caused by a mesenteric desmoid tumour.
|
Eur J Surg Oncol
|
1994
|
0.75
|
|
87
|
Tumour markers in pancreatic cancer.
|
Scand J Gastroenterol Suppl
|
1986
|
0.75
|
|
88
|
Specific staining of human chorionic gonadotropin beta in benign and malignant gastrointestinal tissues with monoclonal antibodies.
|
Histopathology
|
2001
|
0.75
|
|
89
|
Integrating strategic planning and quality management in a multi-institutional system.
|
Qual Manag Health Care
|
1993
|
0.75
|
|
90
|
Enzyme immunoassay for quantification of tenascin in biologic samples.
|
Clin Biochem
|
1995
|
0.75
|
|
91
|
The road to reorganization. A system keeps its regional network all in the family.
|
Health Prog
|
1989
|
0.75
|
|
92
|
Tumour markers in gastric cancer.
|
Ann Chir Gynaecol
|
1989
|
0.75
|
|
93
|
Consistent expression of HGF and c-met in the perinatal lung.
|
Biol Neonate
|
2006
|
0.75
|
|
94
|
Comparability of three assays for carcinoembryonic antigen.
|
Clin Chem
|
1992
|
0.75
|